Patients Decline in overdose deaths ≠ The end of the opioid crisis Since 2001, International Overdose Day has been observed as a moment to remember those lost to overdose and renew society’s commitment to
News Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.
Patients In schizophrenia care, even the support system needs support After a schizophrenia diagnosis, families must learn how to navigate treatment, respond to symptoms, and communicate effectively.
Digital Callyope's AI-powered solution for mental health practitione... The state of the public’s mental health in the UK and Europe is a serious unmet need.
Patients Stronger together: The future of psychiatry in a changing Eu... Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.
R&D 3 big unanswered questions about psychedelics When it comes to psychedelics in the mental health space, there are still some important foundational questions lacking settled answers.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.